Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
QuintilesIMS
Merck
Deloitte
AstraZeneca
Colorcon
Harvard Business School
Dow
Medtronic
Daiichi Sankyo

Generated: February 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,216,969

« Back to Dashboard

Which drugs does patent 9,216,969 protect, and when does it expire?

Patent 9,216,969 protects ORKAMBI and is included in one NDA.

This patent has forty-eight patent family members in twenty-three countries.
Summary for Patent: 9,216,969
Title:Modulators of ATP-binding cassette transporters
Abstract: Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTC"). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
Inventor(s): Ruah; Sara S. Hadida (La Jolla, CA), Hamilton; Matthew (Hackettstown, NJ), Miller; Mark (San Diego, CA), Grootenhuis; Peter D. J. (San Diego, CA), Bear; Brian (Carlsbad, CA), McCartney; Jason (Cardiff by the Sea, CA), Zhou; Jinglan (San Diego, CA)
Assignee: Vertex Pharmaceuticals Incorporated (Boston, MA)
Application Number:13/871,364
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 9,216,969

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Vertex Pharms Inc ORKAMBI ivacaftor; lumacaftor TABLET;ORAL 206038-002 Sep 28, 2016 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Vertex Pharms Inc ORKAMBI ivacaftor; lumacaftor TABLET;ORAL 206038-001 Jul 2, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,216,969

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,659,268 Modulators of ATP-binding cassette transporters ➤ Sign Up
7,956,052 Modulators of ATP-binding cassette transporters ➤ Sign Up
8,461,156 Modulators of ATP-binding cassette transporters ➤ Sign Up
7,973,038 Modulators of ATP-binding cassette transporters ➤ Sign Up
8,318,733 Modulators of ATP-binding cassette transporters ➤ Sign Up
8,741,933 Modulators of ATP-binding cassette transporters ➤ Sign Up
8,324,207 Modulators of ATP-binding cassette transporters ➤ Sign Up
8,012,999 Modulators of CFTR ➤ Sign Up
7,741,321 Modulators of ATP-binding cassette transporters ➤ Sign Up
7,754,739 Modulators of CFTR ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,216,969

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia 2774925 ➤ Sign Up
Slovenia 2404919 ➤ Sign Up
Slovenia 2395002 ➤ Sign Up
Slovenia 1945632 ➤ Sign Up
Russian Federation 2608610 ➤ Sign Up
Russian Federation 2012123372 ➤ Sign Up
Russian Federation 2463303 ➤ Sign Up
Russian Federation 2008122929 ➤ Sign Up
Portugal 2774925 ➤ Sign Up
Portugal 2404919 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
US Department of Justice
Harvard Business School
Fish and Richardson
Citi
Chubb
Boehringer Ingelheim
Teva
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot